Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 舒鼻灵喷雾剂治疗持续性变应性鼻炎发作期肺经伏热证有效性和安全性的随机双盲剂量平行对照多中心临床试验
[Translation] A randomized double-blind, dose-controlled, multicenter clinical trial on the efficacy and safety of Shubiling spray in the treatment of lung meridian latent heat syndrome during the attack period of persistent allergic rhinitis
通过舒鼻灵喷雾剂不同剂量组治疗持续性变应性鼻炎发作期(肺经伏热证),观察治疗前后相关症状体征变化情况,初步探索舒鼻灵喷雾剂治疗持续性变应性鼻炎发作期(肺经伏热证)的有效性和安全性,并进行剂量探索,为下一阶段临床试验设计提供依据。
[Translation] Different dose groups of Shubiling Spray were used to treat persistent allergic rhinitis attacks (Lung Meridian Latent Heat Syndrome), and the changes in related symptoms and signs before and after treatment were observed. The effectiveness and safety of Shubiling Spray in treating persistent allergic rhinitis attacks (Lung Meridian Latent Heat Syndrome) were preliminarily explored, and dose exploration was conducted to provide a basis for the design of the next stage of clinical trials.
100 Clinical Results associated with Changzhou Shenghui Pharmaceutical Co., Ltd
0 Patents (Medical) associated with Changzhou Shenghui Pharmaceutical Co., Ltd
100 Deals associated with Changzhou Shenghui Pharmaceutical Co., Ltd
100 Translational Medicine associated with Changzhou Shenghui Pharmaceutical Co., Ltd